Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

38.69USD
21 Jun 2018
Change (% chg)

$-0.36 (-0.92%)
Prev Close
$39.05
Open
$39.25
Day's High
$39.34
Day's Low
$38.55
Volume
170,371
Avg. Vol
268,077
52-wk High
$41.52
52-wk Low
$23.34

Latest Key Developments (Source: Significant Developments)

Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan
Monday, 2 Apr 2018 07:05am EDT 

April 2 (Reuters) - Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca ::MARKET APPROVAL FOR ITS BRACANALYSIS® DIAGNOSTIC SYSTEM IN JAPAN.MUTATED METASTATIC BREAST CANCER​.  Full Article

Myriad Genetics Receives Subpoena From Department Of Health And Human Services
Monday, 12 Mar 2018 05:50pm EDT 

March 12 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS SAYS RECEIVED SUBPOENA FROM DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF INSPECTOR GENERAL - SEC FILING​.MYRIAD GENETICS - ‍ SUBPOENA CONNECTED WITH INVESTIGATION INTO CLAIMS SUBMITTED FOR PAYMENT UNDER MEDICARE AND MEDICAID​.MYRIAD GENETICS - SUBPOENA REQUESTED CO PRODUCE DOCUMENTS RELATED TO BILLING TO GOVERNMENT-FUNDED HEALTHCARE PROGRAMS FOR HEREDITARY CANCER TESTING.MYRIAD GENETICS INC - ‍TIME PERIOD COVERED BY SUBPOENA IS JANUARY 1, 2014 THROUGH DATE OF ISSUANCE OF SUBPOENA​.MYRIAD GENETICS - NO CLAIMS HAVE BEEN MADE AGAINST CO AT THIS TIME.  Full Article

Myriad Genetics Q2 Adjusted Earnings Per Share $0.31
Tuesday, 6 Feb 2018 04:05pm EST 

Feb 6 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.31.Q2 GAAP EARNINGS PER SHARE $0.45.Q2 REVENUE $194 MILLION.MYRIAD GENETICS - ‍TAX REFORM LEGISLATION WILL POSITIVELY BENEFIT FISCAL 2018 FY ADJUSTED EARNINGS PER SHARE BY ABOUT $0.06 WITH $0.02 RECORDED IN FISCAL Q2​.SEES ‍FISCAL YEAR 2018 REVENUE BETWEEN $760-$770 MILLION​.SEES FY18 GAAP DILUTED EARNINGS PER SHARE ‍$1.82-$1.87​.SEES FY18 ADJUSTED DILUTED EARNINGS PER SHARE ‍$1.11-$1.16​.  Full Article

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
Wednesday, 3 Jan 2018 07:05am EST 

Jan 3 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA.MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED..MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL.  Full Article

Myriad Genetics posts Q1 adjusted earnings per share $0.26
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal first-quarter 2018 financial results.Q1 adjusted earnings per share $0.26.Q1 GAAP earnings per share $1.15.Q1 revenue $190.2 million versus I/B/E/S view $183.4 million.Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees ‍fiscal year 2018 revenue $750 million to $770 million​.Myriad Genetics Inc sees ‍fiscal year 2018 earnings per share $1.41-$1.46​.Myriad Genetics Inc sees ‍fiscal year 2018 adjusted earnings per share $1.00-$1.05​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 revenue $187 million to $189 million​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 earnings per share $0.08-$0.10; sees fiscal second-quarter 2018 adjusted earnings per share $0.22-$0.24​.FY2018 earnings per share view $1.03, revenue view $764.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.25, revenue view $189.9 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan
Tuesday, 24 Oct 2017 07:05am EDT 

Oct 24 (Reuters) - Myriad Genetics Inc :Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer.Myriad Genetics Inc - submitted BRACAnalysis CDX in Japan for review by PMDA and marketing approval by Ministry Of Health, Labor and Welfare​.Myriad Genetics Inc - ‍submitted marketing approval as a companion diagnostic to olaparib for use in HER2- metastatic breast cancer patients​.  Full Article

Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Myriad Genetics Inc :Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer.Myriad Genetics Inc - ‍Myriad expects FDA'S priority review process to conclude in fiscal third-quarter 2018​.  Full Article

Myriad Genetics Inc announces launch of riskScore
Tuesday, 5 Sep 2017 05:23pm EDT 

Sept 5 (Reuters) - Myriad Genetics Inc :Myriad Genetics Inc - September 5, co announced it has launched riskScore - SEC filing.  Full Article

EndoPredict receives positive coverage decisions from Medicare and Anthem
Thursday, 17 Aug 2017 04:15pm EDT 

Aug 17 (Reuters) - Myriad Genetics Inc :EndoPredict receives positive coverage decisions from Medicare and Anthem.Myriad Genetics Inc - ‍Palmetto GBA have announced positive coverage decisions for EndoPredict testing​.Myriad Genetics Inc - ‍Myriad will now have coverage for over 90 percent of breast cancer patients​.  Full Article

Myriad Genetics Q4 adjusted earnings per share $0.30
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal fourth-quarter 2017 and fiscal full-year 2017 financial results.Q4 adjusted earnings per share $0.30.Q4 GAAP earnings per share $0.19.Q4 revenue $200.5 million versus I/B/E/S view $193.7 million.Q4 earnings per share view $0.26 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees fiscal year 2018 revenue $750-$770 million.Myriad Genetics Inc sees fiscal year 2018 GAAP diluted earnings per share $0.37-$0.42.Myriad Genetics Inc sees fiscal year 2018 adjusted earnings per share $1.00-$1.05.Myriad Genetics Inc sees first-quarter 2018 revenue $181-$183 million.Myriad Genetics Inc sees first-quarter 2018 GAAP diluted earnings per share $0.05-$0.07.Myriad Genetics Inc sees first-quarter 2018 adjusted earnings per share $0.19-$0.21.Q1 earnings per share view $0.24, revenue view $191.8 million -- Thomson Reuters I/B/E/S.FY2018 earnings per share view $1.08, revenue view $789.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16

* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2018 FINANCIAL RESULTS